News & Views
Cancer Cells Build Protection Against Viral Therapies
Jun 24 2020 Read 249 Times
Scientists have discovered how cancer cells can protect themselves from viruses that are harmful to tumours but not to healthy cells, opening opportunities for other research leading to improved viral treatments for the disease.
Researchers at the Francis Crick Institute were able to identify a mechanism that protects cancer cells from oncolytic viruses, which are sometimes used as a treatment to destroy cancer cells and stimulate an immune response against the tumour. However, they only work in a minority of patients and the reasons whether they are effective or not are not yet fully understood.
The team examined the environment surrounding a tumour and how cancer cells interact with their neighbours, in particular, cancer-associated fibroblasts (CAFs), which researchers know play a significant role in cancer protection, growth and spread.
They found that when cancer cells are in direct contact with CAFs, this leads to inflammation that can alert the surrounding tissue, making it harder for viruses to invade and replicate within the cancer cell.
This protective inflammatory response occurs when cancer cells pass small amounts of cytoplasm, the fluid in their cells, through to the CAFs. This triggers the fibroblasts to signal to nearby cells to release cytokines, molecules that cause inflammation(1).
Erik Sahai, paper author and group leader of the Tumour Cell Biology Laboratory at the Crick says: “This process only occurs when cancer cells and fibroblasts are in direct contact with each other. In healthy tissue, this type of inflammatory response would only happen during injury, as there is usually a membrane keeping them apart.
“This is an excellent example of the way cancer hijacks our body’s protective mechanisms for its own gain.”
Importantly, when the researchers blocked the signalling pathway in cell cultures and in tumours grown in the laboratory, they found that the cancer cells became more sensitive to oncolytic viruses.
They hope these findings may, in the future, help to develop a treatment that could modulate the inflammation and so help oncolytic viruses to more effectively target cancer cells.
Emma Milford, co-lead author and Phd student in the Tumour Cell Biology Laboratory at the Crick says: “If we can more fully understand how cancer cells protect themselves from oncolytic viruses and find effective ways to stop these protective mechanisms, these viruses could become a more powerful tool doctors can use to treat cancer. This research is an important, early step towards this.”
Antonio Rullan, co-lead author and clinical research fellow in the Tumour Cell Biology Laboratory at the Crick adds: “These viruses prefer to target cancer cells over healthy cells, which has made them of interest for scientists over the last few decades. However, much more remains to be understood about how they interact with tumours and the immune system.”
The researchers plan to continue this work and study exactly how the cytoplasm is transferred from one cell to another.
(1) The transfer of cytoplasm from cancer cells into fibroblasts leads to the activation of STING and IRF3-mediated expression of interferon-β1 and other cytokines.
Published in Nature Cell Biology
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles Chromatography - What is Eluent Generation? - Automated online μSPE Clean-up for QuEChERS Approach to Pesticides Analysis - Simple and Seamless Routine Analysis...
View all digital editions
Jul 27 2020 Kintex, South Korea
Aug 02 2020 Milwaukee, Wisconsin, USA
Aug 03 2020 Lombard, IL, USA
Aug 13 2020 Shanghai, China
Aug 16 2020 San Francisco, CA, USA